Vivus (VVUS) Surges as Qsymia Prescriptions Rise 46%
Tweet Send to a FriendGet Alerts VVUS Hot Sheet
Price: $14.50 +7.25%
Rating Summary:
6 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Rating Summary:
6 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 21 | Down: 24 | New: 29
Trade VVUS Now!
Vivus, Inc. (NASDAQ: VVUS) is stronger early Monday following positive script data.
Analysts at Bloomberg Industries noted that Qsymia prescriptions gained 46% week-over-week, citing data from Symphony Health Solutions.
Shares of Vivus last traded at $12.55, up 9.3 percent.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analysts at Bloomberg Industries noted that Qsymia prescriptions gained 46% week-over-week, citing data from Symphony Health Solutions.
Shares of Vivus last traded at $12.55, up 9.3 percent.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Vivus (VVUS) Sees Upside on Icahn Connection
- UPDATE: Intuitive Surgical (ISRG) Jury Reaches Positive Verdict in Robot Case; Shares Rise
- Analyst Sees Potential for Omeros' (OMER) OMS824 as FDA Gives Clearance
Create E-mail Alert Related Categories
Analyst Comments, FDA, Trader Talk
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
